HomeCompareSHWGF vs ABBV

SHWGF vs ABBV: Dividend Comparison 2026

SHWGF yields 3.85% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHWGF wins by $13.7K in total portfolio value· pulled ahead in Year 9
10 years
SHWGF
SHWGF
● Live price
3.85%
Share price
$0.52
Annual div
$0.02
5Y div CAGR
38.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$116.0K
Annual income
$38,332.89
Full SHWGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SHWGF vs ABBV

📍 SHWGF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHWGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHWGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHWGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHWGF
Annual income on $10K today (after 15% tax)
$326.92/yr
After 10yr DRIP, annual income (after tax)
$32,582.96/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SHWGF beats the other by $11,526.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHWGF + ABBV for your $10,000?

SHWGF: 50%ABBV: 50%
100% ABBV50/50100% SHWGF
Portfolio after 10yr
$109.2K
Annual income
$31,552.33/yr
Blended yield
28.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SHWGF
No analyst data
Altman Z
2.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHWGF buys
0
ABBV buys
0
No recent congressional trades found for SHWGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHWGFABBV
Forward yield3.85%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.1%40.6%
Portfolio after 10y$116.0K$102.3K
Annual income after 10y$38,332.89$24,771.77
Total dividends collected$87.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHWGF vs ABBV ($10,000, DRIP)

YearSHWGF PortfolioSHWGF Income/yrABBV PortfolioABBV Income/yrGap
1$11,231$531.15$11,550$430.00$319.00ABBV
2$12,787$769.94$13,472$627.96$685.00ABBV
3$14,814$1,131.40$15,906$926.08$1.1KABBV
4$17,542$1,691.67$19,071$1,382.55$1.5KABBV
5$21,356$2,585.53$23,302$2,095.81$1.9KABBV
6$26,913$4,062.45$29,150$3,237.93$2.2KABBV
7$35,405$6,607.64$37,536$5,121.41$2.1KABBV
8$49,102$11,218.96$50,079$8,338.38$977.00ABBV
9← crossover$72,621$20,081.68$69,753$14,065.80+$2.9KSHWGF
10$116,037$38,332.89$102,337$24,771.77+$13.7KSHWGF

SHWGF vs ABBV: Complete Analysis 2026

SHWGFStock

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.

Full SHWGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SHWGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHWGF vs SCHDSHWGF vs JEPISHWGF vs OSHWGF vs KOSHWGF vs MAINSHWGF vs JNJSHWGF vs MRKSHWGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.